Author

E. Piskounova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

G. Cascio· 2 shared I. Delclaux· 2 shared K. Aguirre· 2 shared M. Zerhouni· 2 shared O. Elemento· 2 shared R. O. Hughes· 2 shared A. D. Davidson· 1 shared A. Kerelsky· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Cascio

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Selenocysteine tRNA methylation promotes oxidative stress resistance in melanoma metastasis

L. A. Nease, K. P. Church, I. Delclaux, S. Murakami, M. A. Amiama, M. Zerhouni, G. Cascio, R. O. Hughes, P. Zumbo, L. E. Dow, S. R. Jaffrey, D. Betel, E. Piskounova

This study shows that FTSJ1-mediated tRNASec methylation enhances oxidative stress resistance and metastatic colonization in melanoma.

bioRxiv · Oct 2, 2023Cancer Biology

Transcriptional Isoforms of NAD+ Kinase regulate oxidative stress resistance and melanoma metastasis

G. Cascio, K. Aguirre, K. Church, R. O. Hughes, L. Nease, D. Q. Licona, I. Delclaux, M. Zerhouni, E. Piskounova

The paper identifies NADK isoform 3 as a key regulator of oxidative stress resistance and metastasis in melanoma by enhancing NADP(H) pools.

bioRxiv · Feb 2, 2023Cancer Biology

A nuclear cAMP microdomain suppresses tumor growth by Hippo pathway inactivation

M. M. Drozdz, A. S. Doane, R. Alkallas, G. Desman, R. Bareja, M. Reilly, J. Bang, M. Yusupova, J. You, J. Z. Wang, A. Verma, K. Aguirre, E. Kane, I. R. Watson, O. Elemento, , J. H. Zippin

The paper identifies a nuclear cAMP microdomain that suppresses tumor growth by inhibiting YAP in the Hippo pathway.

bioRxiv · Nov 15, 2021Cancer Biology

Cell-type specific requirement for pyruvate dehydrogenase in hematopoiesis and leukemia development.

S. Jun, S. Mahesula, T. P. Mathews, M. S. Martin-Sandoval, Z. Zhao, E. Piskounova, M. Agathocleous

The paper investigates whether metabolic requirements of leukemia cells reflect normal cell type metabolism, finding that PDH is required in T cell progenitors but not other hematopoietic cells.

bioRxiv · May 4, 2021Cancer Biology

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

T. M. Yaron, B. E. Heaton, T. M. Levy, J. L. Johnson, T. X. Jordan, B. M. Cohen, A. Kerelsky, T.-Y. Lin, K. M. Liberatore, D. K. Bulaon, E. R. Kastenhuber, M. N. Mercadante, K. Shobana-Ganesh, L. He, R. E. Schwartz, , M Kavanagh-Williamson

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

bioRxiv · Aug 14, 2020 · PreprintMicrobiology